Clinical trialPhase 1 / Phase 2Completed
A Study of AK112 in Advanced Malignant Tumors
A Phase Ib/II Study of AK112（PD-1 / VEGF Bispecific Antibody） in Combination With AK117（Anti-CD47 Antibody）With or Without Chemotherapy in Advanced Malignant Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 22 January 2022
- Expected end
- 31 December 2025
- Enrollment
- 154 participants
- Sites
- 1
- Primary outcomes
- Number of patients with Adverse Events (AEs); Objective Response Rate (ORR)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 3 March 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117（Anti-CD47 Antibody）with or without chemotherapy in advanced malignant tumors